Targeting ALK Rearrangements in NSCLC: Current State of the Art
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.863461
Abstract: Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the approval of the first-generation ALK inhibitor crizotinib which achieved better results in… read more here.
Keywords: alk inhibitors; generation alk; alk rearrangements; targeting alk ... See more keywords
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancers"
DOI: 10.3390/cancers9120164
Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3–7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved… read more here.
Keywords: cancer; alk fusion; targeting alk; lung cancer ... See more keywords